Oral Session 2-7D Indolent Lymphoma: Novel Therapy

[OS2-7D-1] Analysis of safety and efficacy of ibrutinib for refractory MCL and CLL/SLL

Yoshihiro Kameoka¹, Atsushi Kitabayashi², Kumi Ubukawa¹, Shinsuke Noguchi³, Hideaki Ohyagi⁴, Mutsuhito Motegi⁵, Yoshinari Kawabata², Jin Ogasawara⁶, Jun Kuroki⁷, Takashi Nimura⁵, Naoto Takahashi¹ (1.Hematol., Akita Univ., Akita, Japan, 2.Hematol., Akita Kousei Med. Cen., Akita, Japan, 3.Hematol., Akita Red Cross Hosp., Akita, Japan, 4.Hematol., Hiraka Gen. Hosp., Yokote, Japan, 5.Int., Med., Omagari Kousei Med. Cen., Omagari, Japan, 6.Int., Med., Odate Municipal Gen. Hosp., Odate, Japan, 7.Int., Med., Yuri Kumiai Gen. Hosp., Yurihonjo, Japan)